DexCom (DXCM) has risen sharply, recording gains of 16.74% in the past 4 weeks. However, the stock has corrected -0.77% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 15.55% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 3% and the 50-Day Moving Average is 12.9%. DexCom (NASDAQ:DXCM): On Fridays trading session , Opening price of the stock was $91 with an intraday high of $91. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $90. However, the stock managed to close at $90.53, a loss of 0.43% for the day. On the previous day, the stock had closed at $90.92. The total traded volume of the day was 499,974 shares.
The company Insiders own 2.8% of DexCom shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -5.7% . Institutional Investors own 95.15% of DexCom shares. During last six month period, the net percent change held by insiders has seen a change of -10.48%. Also, Equity analysts at the Brokerage firm Deutsche Bank maintains its rating on DexCom (NASDAQ:DXCM). The rating major has initiated the coverage with buy rating on the shares. The Analysts at Deutsche Bank raises the price target from $90 per share to $98 per share. The rating by the firm was issued on July 15, 2016.
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4, DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patients receiver and an application on the patients iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers, who can remotely monitor a patients glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpots data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.